Annovis Bio Inc (ANVS)
NYSE:ANVS
Want to see ANVS full AI Analyst Report?
Top Page
Annovis Bio
(NYSE:ANVS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▲(6.95% Upside)
Action:Reiterated
Date:05/16/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and sustained negative cash flow with heightened TTM deterioration). Technicals are mixed with neutral momentum but a weak longer-term trend, while valuation metrics provide limited support due to non-meaningful P/E and no dividend. Recent financing improves runway for trials but adds dilution risk, keeping the overall profile below average.
Positive Factors
No debt / balance-sheet flexibility
Having no reported debt removes fixed interest obligations and preserves capital allocation optionality for a clinical-stage biotech. This reduces near-term solvency risk and gives management flexibility to prioritize R&D and milestone-driven spending without servicing debt over the next several quarters.
Negative Factors
Zero revenue; persistent losses
Zero revenues and sustained operating losses mean the company is entirely dependent on external funding until commercialization. Persistent negative EBIT/EBITDA and a very large TTM net loss weaken earnings quality and increase execution risk over the next 2-6 months absent successful trial or partnering outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
No debt / balance-sheet flexibility
Having no reported debt removes fixed interest obligations and preserves capital allocation optionality for a clinical-stage biotech. This reduces near-term solvency risk and gives management flexibility to prioritize R&D and milestone-driven spending without servicing debt over the next several quarters.
Read all positive factors
Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$71.03M
Dividend YieldN/A
Average Volume (3M)1.27M
Price to Earnings (P/E)―
Beta (1Y)2.70
Revenue GrowthN/A
EPS Growth20.55%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.72
Shares Outstanding34,646,870
10 Day Avg. Volume990,199
30 Day Avg. Volume1,269,695
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.25
Revenue Forecast (FY)N/A
Annovis Bio Business Overview & Revenue Model
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheim...
How the Company Makes Money
null...
Annovis Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -41.42M | -29.70M | -26.69M | -45.03M | -25.51M | -14.50M |
| Net Income | -40.92M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
Balance Sheet | ||||||
| Total Assets | 16.24M | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Cash, Cash Equivalents and Short-Term Investments | 14.22M | 19.53B | 10.55M | 5.75M | 28.38M | 45.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 13.12M | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M |
| Stockholders Equity | 3.13M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
Cash Flow | ||||||
| Free Cash Flow | -9.03B | -25.62B | -21.89B | -39.97M | -17.31M | -9.13M |
| Operating Cash Flow | -9.03B | -25.62B | -21.89B | -39.97M | -17.31M | -9.13M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 3.71B | 34.60B | 26.69B | 17.34M | 4.61K | 46.74M |
Annovis Bio Technical Analysis
Negative
1.87
Price Trends
2.15
Negative
2.54
Negative
2.64
Negative
Market Momentum
<0.01
Positive
42.61
Neutral
7.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 1.87 is below the 20-day moving average (MA) of 2.08, below the 50-day MA of 2.15, and below the 200-day MA of 2.64, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 42.61 is Neutral, neither overbought nor oversold. The STOCH value of 7.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.
Annovis Bio Risk Analysis
Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Annovis Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $179.58M | -0.96 | -81.24% | ― | -11.87% | -86.91% | |
52 Neutral | $115.41M | -3.09 | -64.33% | ― | 115.44% | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $210.17M | -2.69 | -79.63% | ― | -100.00% | -1124.16% | |
47 Neutral | $157.46M | -1.80 | -111.27% | ― | ― | 3.91% | |
46 Neutral | $71.03M | ― | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
ANVS
Annovis Bio
1.94
-0.07
-3.48%
WHWK
Whitehawk Therapeutics
4.07
2.15
111.43%
DTIL
Precision BioSciences
6.90
2.25
48.39%
GLSI
Greenwich LifeSciences
26.31
16.58
170.40%
ABOS
Acumen Pharmaceuticals
2.17
1.13
108.65%
COYA
Coya Therapeutics, Inc.
4.57
-1.10
-19.40%
Annovis Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Annovis Bio Prices Registered Direct Offering to Fund Trials
Positive
Apr 10, 2026
On April 9, 2026, Annovis Bio priced an underwritten registered direct offering of 5,263,156 shares of common stock, together with accompanying warrants to purchase an equal number of shares, at a combined price of $1.90 per share and warrant. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.